BioSpace News Archive

Sandoz Inc. today announced the immediate availability in the US of its generic acetaminophen injection, used in adult and pediatric patients two years and older to relieve mild to moderate pain and to treat moderate to severe pain in conjunction with opioid analgesics

When a coronavirus—including SARS-CoV-2, which causes COVID-19—infects someone, it hijacks the person’s cells, co-opting their molecular machinery for its own survival and spread.

Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced its intention to offer and sell shares of its common stock in an underwritten public offering pursuant to an existing shelf registration statement.

Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval of odevixibat for the treatment of patients with progressive familial intrahepatic cholestasis (PFIC)

Zoetis Inc. (NYSE:ZTS) today announced the appointment of Antoinette (Tonie) Leatherberry, an experienced technology strategist and executive, to its Board of Directors

IsoPlexis, the leader in single-cell functional proteomics, announced today that Chief Executive Officer and Co-Founder, Sean Mackay, will present at Citi’s Spotlight on Diagnostics on Thursday, December 17th

Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, announced that it has closed a previously announced private financing with a group of institutional accredited investors led by Bain Capital Life Sciences, with participation from new and existing investors, including Ally Bridge Group, Omega Funds, OrbiMed Advisors, EcoR1 Capital, and Samsara BioCapital.

Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced the closing of its previously announced initial public offering of 13,225,000 shares of its common stock,

Seer, Inc., a life sciences company focused on enabling exceptional scientific outcomes through the power of unbiased, deep, rapid and scalable proteomics information, today announced the closing of its initial public offering of 10,592,106 shares of Class A common stock

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it has received CLIA Licensure from the State of California that permits testing of clinical samples.